246 related articles for article (PubMed ID: 25023007)
1. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.
Boschetti G; Nancey S; Moussata D; Stefanescu C; Roblin X; Chauvenet M; Stroeymeyt K; Bouhnik Y; Flourié B
Dig Liver Dis; 2014 Oct; 46(10):875-80. PubMed ID: 25023007
[TBL] [Abstract][Full Text] [Related]
2. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
6. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.
Hoffmann P; Wehling C; Krisam J; Pfeiffenberger J; Belling N; Gauss A
World J Gastroenterol; 2019 Apr; 25(13):1603-1617. PubMed ID: 30983820
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis.
Yamamoto S; Nakase H; Mikami S; Inoue S; Yoshino T; Takeda Y; Kasahara K; Ueno S; Uza N; Kitamura H; Tamaki H; Matsuura M; Inui K; Chiba T
Aliment Pharmacol Ther; 2008 Sep; 28(5):589-97. PubMed ID: 18549460
[TBL] [Abstract][Full Text] [Related]
8. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients.
Hiraoka S; Kato J; Moritou Y; Takei D; Inokuchi T; Nakarai A; Takahashi S; Harada K; Okada H; Yamamoto K
BMC Gastroenterol; 2015 Apr; 15():53. PubMed ID: 25925267
[TBL] [Abstract][Full Text] [Related]
9. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients.
Miyoshi J; Matsuoka K; Inoue N; Hisamatsu T; Ichikawa R; Yajima T; Okamoto S; Naganuma M; Sato T; Kanai T; Ogata H; Iwao Y; Hibi T
J Crohns Colitis; 2013 Dec; 7(12):e609-14. PubMed ID: 23680174
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy.
Inoue T; Murano M; Narabayashi K; Okada T; Nouda S; Ishida K; Kawakami K; Abe Y; Takeuchi T; Tokioka S; Umegaki E; Higuchi K
Intern Med; 2013; 52(1):15-20. PubMed ID: 23291669
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis.
Yamamoto S; Nakase H; Matsuura M; Masuda S; Inui K; Chiba T
J Clin Gastroenterol; 2011 Jul; 45(6):526-30. PubMed ID: 21336140
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.
Schmidt KJ; Herrlinger KR; Emmrich J; Barthel D; Koc H; Lehnert H; Stange EF; Fellermann K; Büning J
Aliment Pharmacol Ther; 2013 Jan; 37(1):129-36. PubMed ID: 23121200
[TBL] [Abstract][Full Text] [Related]
14. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis.
Kawakami K; Inoue T; Murano M; Narabayashi K; Nouda S; Ishida K; Abe Y; Nogami K; Hida N; Yamagami H; Watanabe K; Umegaki E; Nakamura S; Arakawa T; Higuchi K
World J Gastroenterol; 2015 Feb; 21(6):1880-6. PubMed ID: 25684955
[TBL] [Abstract][Full Text] [Related]
16. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.
Ogata H; Matsui T; Nakamura M; Iida M; Takazoe M; Suzuki Y; Hibi T
Gut; 2006 Sep; 55(9):1255-62. PubMed ID: 16484504
[TBL] [Abstract][Full Text] [Related]
17. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children.
Ziring DA; Wu SS; Mow WS; Martín MG; Mehra M; Ament ME
J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):306-11. PubMed ID: 17873742
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis.
Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H
Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis.
Watson S; Pensabene L; Mitchell P; Bousvaros A
Inflamm Bowel Dis; 2011 Jan; 17(1):22-9. PubMed ID: 20722055
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
